Indapamide Teva Sante (Indapamide)

Indapamide blocks the sodium‑chloride transporter in the distal convoluted tubule of the kidney. This inhibition reduces reabsorption of sodium and chloride, leading to increased urine output, lower plasma volume, and decreased peripheral vascular resistance, which together lower blood pressure.

The appropriate dose of Indapamide Teva Sante is determined by the prescribing healthcare professional based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of indapamide during pregnancy or lactation has not been definitively established. Healthcare providers will weigh potential benefits against possible risks before prescribing it to pregnant or nursing individuals, and alternative treatments may be considered.

To request Indapamide Teva Sante, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indapamide belongs to the thiazide‑like diuretic class and offers a longer duration of action with a lower risk of metabolic disturbances compared with some traditional thiazides. It is often chosen for patients who need effective blood‑pressure control combined with modest diuretic effect, but the choice depends on individual clinical factors.

Indapamide Teva Sante should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

Indapamide Teva Sante is taken orally, usually with a glass of water. The tablet should be swallowed whole and can be taken with or without food, unless the prescriber advises otherwise.

Serious risks include severe dehydration, significant electrolyte disturbances such as hypokalemia, acute gout attacks, allergic reactions like rash or angioedema, and rare blood disorders. Patients should be monitored regularly for these conditions, especially during the initial phases of therapy.

Indapamide is contraindicated in patients with known hypersensitivity to indapamide or other sulfonamide‑derived drugs, severe renal impairment, and in those with anuria. Caution is also advised for individuals with uncontrolled diabetes, gout, or electrolyte imbalances.